Trials such as TRIUMPH-1 and TRANSCEND-T2D-1 reported strong results in 2026, but the full regulatory review process takes additional time before any drug can be legally prescribed or compounded
Liraglutide (Saxenda) was FDA-approved in 2014 for weight-management in adults with overweight and obesity
Paying cash for Kwikpens or single-dose vials of Zepbound, for example, can be a more affordable option
Potential treatment for muscle-wasting diseases IGF-1 LR3 could be a therapeutic option for muscle-wasting conditions and age-related muscle loss (4)
Human application of peptides outside clinical trials is the sole responsibility of the individual
Around 6% of the surveyed population, including participants in France, Germany, Italy, Spain, the UK, the USA, China, Japan, and South Korea, actively use GLP-1s, which creates clear opportunities for companion products